This downregulation may in fact account for the efficacy of RTX in treatment of some autoimmune diseases, by inhibiting FcγR-driven pathological inflammation (the “immune complex decoy hypothesis” [32]). This evidence concerns the gene FCGR2A and autoimmune disease.